TOPLINE In patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced (F2/F3) fibrosis or compensated cirrhosis, efruxifermin 50 mg was associated with improved fibrosis response rates compared with placebo. Among a majority of early fibrosis responders in the efruxifermin group, improvements persisted through week 96. METHODOLOGY MASH is a progressive liver disease involving hepatic fat accumulation …
Read More
MASH: Efruxifermin Linked to Sustained Fibrosis Response
